SUCLG2 and rectosigmoid adenocarcinoma: In one independent study, HIGD1A, SUCLG2, and SLC25A24 were all significantly reduced in various subtypes of colorectal tumors, including cecum adenocarcinoma (n = 22), colon adenocarcinoma (n = 101), colon mucinous adenocarcinoma (n = 22), rectal adenocarcinoma (n = 60), rectal mucinous adenocarcinoma (n = 6), and rectosigmoid adenocarcinoma (n = 3) (Fig. 5b–d).